MosaiQ™ by Quotient

Jefferies Healthcare Conference, London

November 14, 2018

Transfusion diagnostics and beyond

Chris Lindop, Chief Financial Officer

Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E ofthe Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements includestatements regarding our expectations of continued growth, the development, regulatory approval, commercialization, and impact ofMosaiQ and other new products (including our current expectations regarding the timing of MosaiQ project milestones) and forecasts of thedemand for MosaiQ Microarrays and our expected sources of funding. Such statements are based on current assumptions that involve risksand uncertainties that could cause actual outcomes and results to differ materially.

These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances forproducts or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expandedproduct development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect tomanufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding;continued or worsening adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in thecompany's filings with the Securities and Exchange Commission (“SEC”). Investors are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-lookingstatements.

The Quotient logo and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions. Anyimages, schematics or other graphic or pictorial representations contained herein, including those representing the MosaiQ™ Instrument orMicroarrays, are for illustrative purposes only. Those representations may change and may not accurately represent final Quotient productsor services.

This presentation contains statistics and other data that in some cases have been obtained or compiled from information made available bythird parties. Quotient makes no representation or warranty, expressed or implied, with respect to the accuracy, reasonableness orcompleteness of such information.

November 14, 2018 The MosaiQ system is not yet commercially available or approved by any government agency 2

Quotient: an established manufacturer of transfusion diagnostics

Eysins, Switzerland Global headquarters and MosaiQ microarray manufacturing

Edinburgh, United Kingdom Reagent business and MosaiQ product development

Newtown – Pennsylvania, USA US Commercial base

History 2018 – 72 reagents products CE marked and 63 FDA licensed

2014 – Quotient Suisse SA formed and Quotient IPO on Nasdaq

2007 – Quotient founded and acquired Alba Bioscience

1998 – Diagnostics Scotland (later renamed Alba Bioscience) created from merger of NRU and Scottish Antibody Production Unit

1990 – Scottish National Blood Services creates National Reagents Unit

3

Innovating for transfusion laboratories for over 30 years

November 14, 2018

Transfusion diagnostics testingNeeds three different testing modalities on the donor side

Serological Disease Screening

Blood GroupingIncl. Extended Antigen Typing

Molecular Disease Screening

4November 14, 2018

Blood transfusionA long and complex value chain

Donor goes to blood collection centre

Blood donationcollected

Blood samples sent to lab for testing

Suitable blood unitsstored at blood bank

Blood units deliveredto hospital

Hospital checks blood compatibility for patient

Patient transfused with suitable units

5November 14, 2018

Transfusion diagnostics market overviewGlobal market value of $3.4 billion*

Donor Testing2/3

Patient Testing1/3

IH

$325mSDS

$875mMDS

$1,100mIH

$1,100m

Concentrated marketUS customers: 2 playersEuropean customers: 2-25 per countryTest volume: high

Fragmented marketUS customers: most hospitalsEurope customers: most hospitalsTest volume: low

* Source: BCC Research, The Global Blood Industry, March 2015

6November 14, 2018

Potential for increasing efficiency in the labDonor testing today requires multiple platforms, modalities and techniques

Expanded IH & initial SDS

Blood grouping

SDS (CMV & Syphilis)

Blood grouping only Manual Testing

SDS

MDS

MDS

Expanded SDS

7November 14, 2018

Transfusion diagnostics marketFragmented market with many high specialized players

Sources: LEK, 2016; and Quotient

IH

SDS

MDS

8November 14, 2018

Transfusion diagnostics marketMosaiQ has the potential to cover all three types of diagnostic testing with one single technology

Sources: LEK, 2016; and Quotient

IH

SDS

MDS

November 14, 2018 9

Experts’ points of viewExperienced leaders in testing labs share the issues they see

Prof M SchmidtHead of Blood Donor ScreeningGerman Red CrossBaden-Württemberg, Hesse

Mr B BlockPresident & CEOBlood Centers of America

Dr P WilliamsonVice PresidentOperations & Scientific AffairsCreative Testing Solutions

Multiple instruments

Different instruments needed, adding complexity and taking up space

Need to increase walk-away time

Dr E CastroHead of Donor TypingBlood Donor Center, Valencia

Lack of innovation

Sector ripe for innovation

Techniques & technologies not evolved

Inefficient workflow

Many steps not automated, requiring human intervention

Extensive use of manual testing

Shortage of trained technicians

More demands & complexity

More demands due to ageing population

No compromise on safety or quality

10November 14, 2018

Quotient has listened to the market and its customersMosaiQ has been designed to provide needed solutions and outcomes

One technology

Comprehensive IH characterization

Serological disease screening

Molecular disease screening

Better resource management

Reduced sample volumes

Longer reagent shelf life

Fewer sample tubes

Improved workflow

Fully automatic process

Reduced testing time

Reduced manual testing

Increasing lab efficiency and improving clinical practice

11November 14, 2018

Creating value for customers, shareholders and QuotientMoving to a new paradigm: Focusing on total cost per donation

Direct & associated testing costs

Non-direct costs

Cost-saving potential

Non-direct costs

Associated testing costs

Direct testing costs

Current practice Quotient

12November 14, 2018

The MosaiQ microarray

Innovative microarray-enabled approach to transfusion diagnostics

Over $300m invested since 2012

Manufacturing capability completed

Automated testing platform completed

Initial IH microarray EU field trials successfully completed and submitted for CE marking

Low-cost multiplex solution is adaptable to multiple menus and testing methods

13November 14, 2018

The MosaiQ all-in-one systemPioneering, patented and proprietary technology platform

14November 14, 2018

MosaiQ EU Field Trial: Concordance data for initial IH Menu

A B D C c E e Cw K k

Concordance 99.9% 99.4% 99.5% 99.9% 99.6% 100.0% 99.9% 100.0% 99.9% 100.0%

Greater than 3,000 donations tested in the concordance portion of field trial

Blood Group Antigen – Required to be 99% concordant with the predicate

The above results imply overall concordance of 99.8% for the MosaiQ antigen typing microarray

Antibody Detection

Concordance 97.5%

Antibody Detection – Required to be 95% concordant with the predicate

Source: Quotient media release, “Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key regulatory audits of its new BioCampus facility” - 25 September 2018

15November 14, 2018

Development overviewThree major technology development projects in parallel

Manufacturing

Instrument

Microarray

16November 14, 2018

ISO 13485 audit completed without findings

MosaiQ DeviceCE Marked

CE mark submission in late September 2018

Go-to-market: Regulatory and commercial milestonesOutlook of current and upcoming menu expansion

ExpandedMosaiQ™ SDS Microarray

Expanded MosaiQ™ IH Microarray

Initial MosaiQ™ IH Microarray

InitialMosaiQ™ SDS Microarray

MosaiQ™ MDS Microarray

Potential screening panels e.g. allergies, women’s health, etc

CY2018 CY2019EU EU

EU

US US & EU

EU US

Development to field trials

Feasibility to early development

Feasibility

DevelopmentInvitation to tender on approvalPlanning

SubmissionField Trials

17November 14, 2018

The addressable market could expand to other diagnostic areasPotential global transfusion market and beyond

SDS MDS

Donor Testing

IH

Other Screening Applications

Allergies Women’s health

Other panels

Patient Testing

IH

18November 14, 2018

Takeaways

30-year heritage and expertise in the development and commercialisation of transfusion diagnostics

Significant investment, development progress and de-risking of MosaiQtechnology

Technology applicable in transfusion diagnostics and beyond

19November 14, 2018 The MosaiQ system is not yet commercially available or approved by any government agency

MosaiQ™ by Quotient

Jefferies Healthcare Conference, London

November 14, 2018

Transfusion diagnostics and beyond

Chris Lindop, Chief Financial Officer

Chris Lindop – Chief Financial Officer - Quotient

21November 14, 2018 The MosaiQ system is not yet commercially available or approved by any government agency

Chris Lindop joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2017.

Mr Lindop has more than 15 years of experience in senior finance leadership roles with public healthcare companies. He previously worked as Chief Financial Officer of Haemonetics Corporation (NYSE:HAE), a global leader in blood processing technology and as Chief Financial Officer of Inverness Medical Innovations, Inc., a global developer, manufacturer and marketer of medical diagnostic products.

In addition, Mr Lindop was a non-executive director of Parexel International Corporation (NASDAQ: PRXL) from 2006, where he was chairman of the audit and finance committee and a member of the nominating and governance committee until its sale.

Previously, he served as an audit partner with the Boston office of Ernst & Young LLP and with the Boston office of Arthur Andersen LLP. He holds a BA in Business from the University of Strathclyde (Scotland).

Contact: chris.lindop@quotientbd.com – D: +41 22 545 52 26 / M: + 41 79 961 69 38

Quotient Suisse SA - Business Park Terre Bonne – Route de Crassier 13 – 1262 Eysins – Switzerland

MosaiQ™ by Quotient

Jefferies Healthcare Conference, London

November 14, 2018

Transfusion diagnostics and beyond

Chris Lindop, Chief Financial Officer